标题：Research Grade Tezepelumab特折鲁单抗,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/89.html
名称：Research Grade Tezepelumab特折鲁单抗
别名：Tezepelumab特折鲁单抗，AMG157, AMG-157, MEDI-9929, MEDI9929, anti-TSLP-Receptor (TSLP-R, Crl2)
CAS: 1572943-04-4
货号：DHJ36101
适用物种：Human
寄主物种：Homo sapiens
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG2-lambda
应用：Research Grade Biosimilar
UniProt：Q969D9
用途范围：仅用于科研
靶点：TSLP, Thymic stromal lymphopoietin
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. PMID: 33979488
Tezepelumab: First Approval. PMID: 35184265
Tezepelumab in Adults with Uncontrolled Asthma. PMID: 31034183
Tezepelumab. PMID: 36810033
Tezepelumab in patients with allergic and eosinophilic asthma. PMID: 38146651
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. PMID: 36702146
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. PMID: 36538979
Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma. PMID: 37724378
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. PMID: 37015033
Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies. PMID: 37772607
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. PMID: 34913186
Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma. PMID: 36470789
Tezepelumab for asthma. PMID: 36651067
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. PMID: 33050934
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. PMID: 35364018
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. PMID: 34256031
Tezepelumab-ekko. PMID: 35108361
Positioning of Tezepelumab in Severe Asthma. PMID: 37812191
Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study. PMID: 36507576
Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis. PMID: 36425526
Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis. PMID: 35269440
Tezepelumab in the Treatment of Uncontrolled Severe Asthma. PMID: 35535458
Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR). PMID: 37619779
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial. PMID: 36223848
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. PMID: 37692126
Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. PMID: 31549891
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). PMID: 34049943
Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis. PMID: 37191902
DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. PMID: 33087119
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. PMID: 33050928
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. PMID: 35570578
Is tezepelumab more than just an anti-eosinophil drug? PMID: 34972684
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study. PMID: 37263380
The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials. PMID: 36601189
Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma. PMID: 37496871
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. PMID: 33922072
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. PMID: 30550828
Dupilumab and tezepelumab in severe refractory asthma: new opportunities. PMID: 35655942
[Tezepelumab: a new option for the treatment of severe asthma]. PMID: 37995367
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types. PMID: 38524099
